Principal Financial Group Inc. Cuts Holdings in Collegium Pharmaceutical, Inc. $COLL

Principal Financial Group Inc. lowered its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 10.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,309,771 shares of the specialty pharmaceutical company’s stock after selling 157,104 shares during the period. Principal Financial Group Inc. owned about 4.16% of Collegium Pharmaceutical worth $45,829,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also made changes to their positions in the company. Federated Hermes Inc. increased its stake in shares of Collegium Pharmaceutical by 67.0% during the third quarter. Federated Hermes Inc. now owns 872 shares of the specialty pharmaceutical company’s stock worth $31,000 after buying an additional 350 shares during the period. CWM LLC grew its holdings in Collegium Pharmaceutical by 453.9% during the 2nd quarter. CWM LLC now owns 1,407 shares of the specialty pharmaceutical company’s stock worth $42,000 after acquiring an additional 1,153 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Collegium Pharmaceutical by 744.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,484 shares of the specialty pharmaceutical company’s stock valued at $73,000 after purchasing an additional 2,190 shares during the last quarter. NewEdge Advisors LLC raised its holdings in shares of Collegium Pharmaceutical by 304.6% in the 2nd quarter. NewEdge Advisors LLC now owns 3,047 shares of the specialty pharmaceutical company’s stock valued at $90,000 after purchasing an additional 2,294 shares in the last quarter. Finally, EMC Capital Management acquired a new stake in shares of Collegium Pharmaceutical in the 2nd quarter valued at $97,000.

Collegium Pharmaceutical Stock Up 1.4%

Collegium Pharmaceutical stock opened at $48.18 on Thursday. The company has a market capitalization of $1.52 billion, a P/E ratio of 29.93 and a beta of 0.64. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.27 and a current ratio of 1.36. Collegium Pharmaceutical, Inc. has a fifty-two week low of $23.23 and a fifty-two week high of $50.79. The stock has a 50-day simple moving average of $47.37 and a 200-day simple moving average of $40.48.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Thursday, November 6th. The specialty pharmaceutical company reported $2.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.89 by $0.36. Collegium Pharmaceutical had a return on equity of 102.03% and a net margin of 7.72%.The firm had revenue of $209.36 million for the quarter, compared to the consensus estimate of $191.25 million. During the same quarter last year, the business posted $1.61 EPS. The firm’s quarterly revenue was down 18.9% compared to the same quarter last year. Equities research analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts recently commented on COLL shares. Weiss Ratings reiterated a “buy (b-)” rating on shares of Collegium Pharmaceutical in a research note on Monday, December 29th. Wall Street Zen raised Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Barclays cut their target price on Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating on the stock in a research report on Friday, January 9th. Zacks Research cut Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th. Finally, Truist Financial set a $55.00 price target on Collegium Pharmaceutical in a report on Wednesday, January 7th. Five analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, Collegium Pharmaceutical currently has a consensus rating of “Moderate Buy” and a consensus target price of $52.80.

Insider Buying and Selling at Collegium Pharmaceutical

In related news, EVP Scott Dreyer sold 17,600 shares of the company’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $48.17, for a total value of $847,792.00. Following the completion of the sale, the executive vice president owned 103,613 shares in the company, valued at $4,991,038.21. This represents a 14.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Rita J. Balice-Gordon sold 3,650 shares of the firm’s stock in a transaction on Friday, December 5th. The stock was sold at an average price of $47.03, for a total transaction of $171,659.50. Following the transaction, the director directly owned 52,629 shares in the company, valued at $2,475,141.87. The trade was a 6.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 2.51% of the stock is owned by corporate insiders.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.